The Pulmonary Drug Delivery Systems market size is USD 55.8 Bn in 2026.
The Pulmonary Drug Delivery Systems market is projected to grow at a CAGR of 5% by 2033.
The Pulmonary Drug Delivery Systems market growth drivers include rising prevalence of COPD and asthma, increasing adoption of inhalation therapies, and technological advancements such as smart inhalers.
North America is a dominating region for Pulmonary Drug Delivery Systems market.
GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., and Koninklijke Philips N.V. are some leading industry players in the Pulmonary Drug Delivery Systems market.